Summary of Study ST003882

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002435. The data can be accessed directly via it's Project DOI: 10.21228/M8WG2J This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003882
Study TitleLipidomic alterations after a single session with ayahuasca in health and depression: a randomized placebo-controlled trial
Study SummaryMajor depressive disorder (MDD) affects 3.8 % of the world population and there is an estimative that at least 30 % of patients have partial or no response to treatments, which is a relevant healthcare concern. Ayahuasca is an indigenous psychedelic beverage, usually prepared from Banisteriopsis caapi and Psychotria viridis, which has been described in the scientific literature as presenting antidepressant effects. In order to investigate the mechanisms behind MDD and ayahuasca treatment at a molecular level, untargeted lipidomic analyses were carried out on blood serum samples from patients diagnosed with treatment-resistant depression (TRD) and control subjects given ayahuasca or placebo in a double-blind design. Results indicated the participation mainly of the immune system in TRD pathophysiology and in the antidepressant effects of ayahuasca, as well as the involvement of hypothalamic-pituitary-adrenal (HPA) axis and microbiota.
Institute
University of Campinas
DepartmentChemistry's Institute
LaboratoryLaboratory of Bioanalytics and Integrated Omics
Last NameMatos
First NameTaynara
AddressRua Josué de Castro, s/n – Cidade Universitária, 13083-970, Campinas – SP, Brazil
Emailt262827@dac.unicamp.br
Phone(85)996154192
Submit Date2025-04-25
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2025-05-16
Release Version1
Taynara Matos Taynara Matos
https://dx.doi.org/10.21228/M8WG2J
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR002435
Project DOI:doi: 10.21228/M8WG2J
Project Title:Lipidomic alterations after a single session with ayahuasca in health and depression: a randomized placebo-controlled trial
Project Type:MS untargeted analysis
Project Summary:Major depressive disorder (MDD) affects 3.8 % of the world population and there is an estimative that at least 30 % of patients have partial or no response to treatments, which is a relevant healthcare concern. Ayahuasca is an indigenous psychedelic beverage, usually prepared from Banisteriopsis caapi and Psychotria viridis, which has been described in the scientific literature as presenting antidepressant effects. In order to investigate the mechanisms behind MDD and ayahuasca treatment at a molecular level, untargeted lipidomic analyses were carried out on blood serum samples from patients diagnosed with treatment-resistant depression (TRD) and control subjects given ayahuasca or placebo in a double-blind design. Results indicated the participation mainly of the immune system in TRD pathophysiology and in the antidepressant effects of ayahuasca, as well as the involvement of hypothalamic-pituitary-adrenal (HPA) axis and microbiota.
Institute:University of Campinas
Department:Chemistry's Institute
Laboratory:Laboratory of Bioanalytics and Integrated Omics
Last Name:Matos
First Name:Taynara
Address:Rua Josué de Castro, s/n – Cidade Universitária, 13083-970, Campinas – SP, Brazil
Email:t262827@dac.unicamp.br
Phone:(85)996154192

Subject:

Subject ID:SU004017
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Male and female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Sample source
SA426761ORG22_NEGCA Blood serum
SA426762ORG76_NEGCA Blood serum
SA426763ORG100_NEGCA Blood serum
SA426764ORG121_NEGCA Blood serum
SA426765ORG1_NEGCA Blood serum
SA426766ORG56_NEGCA Blood serum
SA426767ORG54_NEGCA Blood serum
SA426768ORG109_NEGCA Blood serum
SA426769ORG5_NEGCA Blood serum
SA426770ORG92_NEGCA Blood serum
SA426771ORG38_NEGCA Blood serum
SA426772ORG4_NEGCA Blood serum
SA426773ORG98_NEGCA Blood serum
SA426774ORG33_NEGCP Blood serum
SA426775ORG110_NEGCP Blood serum
SA426776ORG14_NEGCP Blood serum
SA426777ORG47_NEGCP Blood serum
SA426778ORG12_NEGCP Blood serum
SA426779ORG118_NEGCP Blood serum
SA426780ORG66_NEGCP Blood serum
SA426781ORG113_NEGCP Blood serum
SA426782ORG41_NEGCP Blood serum
SA426783ORG16_NEGCP Blood serum
SA426784ORG43_NEGCP Blood serum
SA426785ORG72_NEGCP Blood serum
SA426786ORG74_NEGCP Blood serum
SA426787ORG102_NEGCP Blood serum
SA426788ORG81_NEGCP Blood serum
SA426789ORG106_NEGCP Blood serum
SA426790ORG64_NEGC Blood serum
SA426791ORG96_NEGC Blood serum
SA426792ORG95_NEGC Blood serum
SA426793ORG45_NEGC Blood serum
SA426794ORG46_NEGC Blood serum
SA426795ORG93_NEGC Blood serum
SA426796ORG31_NEGC Blood serum
SA426797ORG49_NEGC Blood serum
SA426798ORG26_NEGC Blood serum
SA426799ORG9_NEGC Blood serum
SA426800ORG51_NEGC Blood serum
SA426801ORG85_NEGC Blood serum
SA426802ORG83_NEGC Blood serum
SA426803ORG111_NEGC Blood serum
SA426804ORG19_NEGC Blood serum
SA426805ORG80_NEGC Blood serum
SA426806ORG79_NEGC Blood serum
SA426807ORG13_NEGC Blood serum
SA426808ORG78_NEGC Blood serum
SA426809ORG59_NEGC Blood serum
SA426810ORG108_NEGC Blood serum
SA426811ORG60_NEGC Blood serum
SA426812ORG73_NEGC Blood serum
SA426813ORG112_NEGC Blood serum
SA426814ORG91_NEGDA Blood serum
SA426815ORG37_NEGDA Blood serum
SA426816ORG03_NEGDA Blood serum
SA426817ORG20_NEGDA Blood serum
SA426818ORG107_NEGDA Blood serum
SA426819ORG24_NEGDA Blood serum
SA426820ORG117_NEGDA Blood serum
SA426821ORG97_NEGDP Blood serum
SA426822ORG82_NEGDP Blood serum
SA426823ORG40_NEGDP Blood serum
SA426824ORG104_NEGDP Blood serum
SA426825ORG114_NEGDP Blood serum
SA426826ORG42_NEGDP Blood serum
SA426827ORG25_NEGDP Blood serum
SA426828ORG52_NEGDP Blood serum
SA426829ORG120_NEGD Blood serum
SA426830ORG6_NEGD Blood serum
SA426831ORG36_NEGD Blood serum
SA426832ORG8_NEGD Blood serum
SA426833ORG10_NEGD Blood serum
SA426834ORG101_NEGD Blood serum
SA426835ORG34_NEGD Blood serum
SA426836ORG30_NEGD Blood serum
SA426837ORG11_NEGD Blood serum
SA426838ORG70_NEGD Blood serum
SA426839ORG65_NEGD Blood serum
SA426840ORG21_NEGD Blood serum
SA426841ORG119_NEGD Blood serum
SA426842Blank1_3NEGNot applicable Not applicable
SA426843QC3_2NEGNot applicable Not applicable
SA426844QC2_3NEGNot applicable Not applicable
SA426845QC2_2NEGNot applicable Not applicable
SA426846QC2_1NEGNot applicable Not applicable
SA426847QC1_4NEGNot applicable Not applicable
SA426848QC1_3NEGNot applicable Not applicable
SA426849QC1_2NEGNot applicable Not applicable
SA426850QC1_1NEGNot applicable Not applicable
SA426851Blank2_4NEGNot applicable Not applicable
SA426852Blank1_2NEGNot applicable Not applicable
SA426853Blank1_4NEGNot applicable Not applicable
SA426854Blank1_5NEGNot applicable Not applicable
SA426855Blank1_6NEGNot applicable Not applicable
SA426856Blank1_7NEGNot applicable Not applicable
SA426857Blank2_2NEGNot applicable Not applicable
SA426858Blank2_3NEGNot applicable Not applicable
SA426859Blank2_5NEGNot applicable Not applicable
SA426860MeOH1Not applicable Not applicable
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 102

Collection:

Collection ID:CO004010
Collection Summary:Blood serum from treatment-resistant depression patients and healthy controls were obtained at the Onofre Lopes University Hospital of the Federal University of Rio Grande do Norte (UFRN, Natal, Brazil) and analyzed at the Institute of Chemistry of the University of Campinas (UNICAMP, Campinas, Brazil). Samples were stored at -80°C until analysis.
Sample Type:Blood (serum)
Collection Location:Onofre Lopes University Hospital of the Federal University of Rio Grande do Norte (UFRN, Natal, Brazil)
Storage Conditions:-80℃

Treatment:

Treatment ID:TR004026
Treatment Summary:Blood serum from TRD patients and healthy controls were obtained at the Onofre Lopes University Hospital (Natal, Brazil) and analyzed at the Institute of Chemistry of the University of Campinas (UNICAMP, Campinas, Brazil). Samples were stored at -80°C until analysis.

Sample Preparation:

Sampleprep ID:SP004023
Sampleprep Summary:After defrosting, serum samples were extracted using a micro-scale liquid-liquid extraction technique: 30 µL of serum sample were transferred to a 2 mL vial, followed by the addition of 225 µL of methanol, 750 µL of methyl-tert-butyl ether, and agitation in a vortex mixer for 20 s. Then, 188 µL of 0.1 % (m/m) ammonium acetate was added, followed by agitation in vortex for 20 s and centrifugation at 10000 g at 4°C for 10 minutes (Hettich Zentrifugen Mikro 220R, Tuttlingen, Germany). The organic supernatant was transferred to a 2 mL vial and solvent content was evaporated in a Speed Vac vacuum concentrator (Eppendorf AG, Hamburg, Germany), resulting in the isolated lipidome.
Sampleprep Protocol Filename:SamplePreparation_LipidomicsNeg.pdf

Chromatography:

Chromatography ID:CH004837
Chromatography Summary:Lipidomic analyses were carried out in an ultra-high performance liquid chromatography (UHPLC) system (UltiMate 3000 RSLCano system, Thermo Scientific, Waltham, USA) coupled to a mass spectrometer equipped with electrospray ionization (ESI) and Orbitrap mass analyzer (Orbitrap Q-Exactive, Thermo Scientific, Waltham, USA). For the chromatographic separation, an ACQUITY UPLC® BEH C18 column with dimensions of 2,1 x 50 mm and particle size 1,7 μm (Waters, Milford, USA) and two mobile phases were used. Mobile phase A consisted in acetonitrile and water (40:60) and mobile phase B consisted of acetonitrile and isopropanol (10:90), both containing 10 mmol/L ammonium acetate. 5 μL of sample (resuspended in 400 μL of a solvent mixture containing 40 % mobile phase B and 60 % mobile phase A) were injected and the following gradient was set (expressed in terms of mobile phase B): 40 % B for 2 min, 50 % B for 3 min, gradual increase to 70 % B for 2 min, 70 % B for 1 min, gradual increase to 100 % B for 2 min, 100 % B for 1 min, gradual decrease to 40 % B for 1 min and 40 % B for 2 min, resulting in 14 min run time. Sampler temperature was set to 10 °C and column and oven temperature to 40 °C.
Instrument Name:Thermo Scientific UltiMate™ 3000 UHPLC RSLCnano system
Column Name:Waters ACQUITY UPLC BEH C18 (50 x 2.1 mm, 1.7 µm)
Column Temperature:40
Flow Gradient:250 µL/min: ): 40 % B for 2 min, 50 % B for 3 min, gradual increase to 70 % B for 2 min, 70 % B for 1 min, gradual increase to 100 % B for 2 min, 100 % B for 1 min, gradual decrease to 40 % B for 1 min and 40 % B for 2 min
Flow Rate:250 µL/min
Solvent A:40% acetonitrile/60% water; 10 mM ammonium acetate
Solvent B:10% acetonitrile/90% isopropanol; 10 mM ammonium acetate
Chromatography Type:Reversed phase

Analysis:

Analysis ID:AN006376
Analysis Type:MS
Analysis Comments:Mass spectrometry analyses were conducted in negative ESI mode from m/z 100 to 1500 in profile mode and at resolution 70000 (at m/z = 200). Heated-ESI parameters were set as spray voltage: - 3.2 kV, capillary temperature: 300 °C, sheath gas flow rate: 35 L/min. The samples were analyzed in a randomized batch. Quality control (QC) samples, consisting of a pool of equal volumes of the samples analyzed in the batch, were analyzed repeatedly and interspersed with the clinical samples, to measure equipment fluctuations and ensure data quality.
Chromatography ID:CH004837
Has Mz:1
Has Rt:1
Rt Units:Minutes
Results File:ST003882_AN006376_Results.txt
Units:Peak area
  logo